Anthony Olszanski

Anthony Olszanski

Fox Chase Cancer Center - Philadelphia / United States
Medical and Health Sciences / Pharmacy & Pharmaceutical Sciences
AD Scientific Index ID: 4617862
-
person_outline Anthony Olszanski's MOST POPULAR ARTICLES
1-) Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapyA Ribas, R Dummer, I Puzanov, A VanderWalde, RHI Andtbacka, ...Cell 170 (6), 1109-1119. e10, 201713152017
2-) Management of immunotherapy-related toxicities, version 1.2019, NCCN clinical practice guidelines in oncologyJA Thompson, BJ Schneider, J Brahmer, S Andrews, P Armand, S Bhatia, ...Journal of the National Comprehensive Cancer Network 17 (3), 255-289, 20195282019
3-) Cutaneous melanoma, version 2.2019, NCCN clinical practice guidelines in oncologyDG Coit, JA Thompson, MR Albertini, C Barker, WE Carson, C Contreras, ...Journal of the National Comprehensive Cancer Network 17 (4), 367-402, 20194022019
4-) NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020: featured updates to the NCCN guidelinesJA Thompson, BJ Schneider, J Brahmer, S Andrews, P Armand, S Bhatia, ...Journal of the National Comprehensive Cancer Network 18 (3), 230-241, 20204012020
5-) Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase I results from a multicenter, open-label phase I/II trial (ECHO-202/KEYNOTE-037)TC Mitchell, O Hamid, DC Smith, TM Bauer, JS Wasser, AJ Olszanski, ...Journal of Clinical Oncology 36 (32), 3223-3230, 20183342018